Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?

被引:0
|
作者
Erden, A. [1 ]
Batu, E. D. [2 ]
Sari, A. [1 ]
Sonmez, H. E. [2 ]
Armagan, B. [1 ]
Demir, S. [2 ]
Firat, E. [3 ]
Bilginer, Y. [2 ]
Bilgen, S. A. [1 ]
Karadag, O. [1 ]
Kalyoncu, U. [1 ]
Kiraz, S. [1 ]
Ertenli, I. [1 ]
Ozen, S. [2 ]
Akdogan, A. [1 ]
机构
[1] Hacettepe Univ, Div Rheumatol, Dept Internal Med, Fac Med, Ankara, Turkey
[2] Hacettepe Univ, Div Rheumatol, Dept Paediat, Fac Med, TR-06100 Ankara, Turkey
[3] Hacettepe Univ, Dept Internal Med, Fac Med, Ankara, Turkey
关键词
familial Mediterranean fever; colchicine resistance; colchicine unresponsiveness; RECOMMENDATIONS; ASSOCIATION; MANAGEMENT; DIAGNOSIS; ANAKINRA; CRITERIA; CHILDREN; SCORE; FMF;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Colchicine is the main therapy for familial Mediterranean fever (FMF); however, 5-10% of patients are colchicine-resistant. There is no standard and validated definition for colchicine resistance. We aimed to compare the existing definitions for colchicine resistance in both adult and paediatric FMF patients to find out the best definition to determine colchicine-resistant patients. Methods. 385 FMF patients were evaluated and patients receiving antiinterleukin-1 treatment were included. The anti-IL-1 therapy had been initiated by the experts in the past based on their experience. Eleven different definitions (found out after PubMed search for colchicine resistance in FMF) were applied to all patients. Results were re-analysed after excluding the patients who had no clinical attacks but persistently high acute phase reactants (APRs) and/or amyloidosis. Results. Sixty patients (40 adults/20 children) who had been using anti-IL-1 therapy were included into this study as colchicine-resistant patients. The highest percentage of patients fulfilled definition 5 (93.3%). Definition 9 had the poorest performance (26%). Significantly, a higher percentage of adult patients met definitions 4 and 6 than paediatric patients (87.5% vs. 50%, p= O. O02; 75% vs. 40%, p= O. O08, respectively). After excluding patients without clinical attacks, the highest percentage of patients fulfilled definition 2 (94.4%). We combined the attack frequency (> 1 typical episode/3 months) in definition 2 and presence of amyloidosis/APR increase (increase in ! 2/3 APRs) in definition 5 to create a new definition which was met by 59 (98.3%) colchicine-resistantF MF patients. Conclusion. Definition of colchicine resistance is still controversial. Definitions with both clinical and laboratory criteria were met by a higher percentage of resistant patients than those without laboratory criteria. However, the proper definitions for the attack-free period and persistence of APRs are still lacking.
引用
收藏
页码:S97 / S102
页数:6
相关论文
共 50 条
  • [21] Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis
    Sozeri, Betul
    Kasapcopur, Ozgur
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (16) : 1986 - 1991
  • [22] PHARMACOKINETICS OF COLCHICINE IN PEDIATRIC AND ADULT PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER
    Berkun, Y.
    Wason, S.
    Brik, R.
    Butbul, Y.
    Ben-Chetrit, E.
    Hashkes, P. J.
    Livneh, A.
    Ozen, S.
    Ozdogan, H.
    Faulkner, R.
    Davis, M. W.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2012, 25 (04) : 1121 - 1130
  • [23] Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
    Sener, Seher
    Cam, Veysel
    Batu, Ezgi Deniz
    Kasap Cuceoglu, Muserref
    Balik, Zeynep
    Aliyev, Emil
    Bayindir, Yagmur
    Basaran, Ozge
    Bilginer, Yelda
    Ozen, Seza
    RHEUMATOLOGY, 2023, 62 (11) : 3700 - 3705
  • [24] Intestinal malrotation as a misdiagnosis of pediatric colchicine resistant familial Mediterranean fever
    Heshin-Bekenstein, Merav
    Hashkes, Philip J.
    PEDIATRIC RHEUMATOLOGY, 2015, 13
  • [25] Approach to the patients with inadequate response to colchicine in familial Mediterranean fever
    Gul, Ahmet
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2016, 30 (02): : 296 - 303
  • [26] Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients
    BodakcI, Erdal
    Yasar Bilge, Nazife Sule
    AtaS, Nuh
    Armagan, Berkan
    Satis, Hasan
    Sari, Alper
    Bilici Salman, Reyhan
    Yardimci, Gozde Kubra
    Babaoglu, Hakan
    Kilic, Levent
    Akif Ozturk, Mehmet
    Goker, Berna
    Haznedaroglu, Seminur
    Kalyoncu, Umut
    Tufan, Abdurrahman
    Kasifoglu, Timucin
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (04) : 1706 - 1711
  • [27] Analysis of polymorphisms in the colchicine binding site of tubulin in colchicine-resistant familial Mediterranean fever patients
    Akbaba, Tayfun Hilmi
    Ustabas, Gizem
    Kasap-Cuceloglu, Muserref
    Ozen, Seza
    Balci-Peynircioglu, Banu
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (11) : 9005 - 9011
  • [28] Colchicine resistance and low vitamin D in familial Mediterranean fever
    Anik, A.
    Abaci, A.
    Unsal, E.
    Makay, B.
    RENAL FAILURE, 2016, 38 (02) : 340 - 341
  • [29] COLCHICINE CONCENTRATION IN LEUKOCYTES OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER
    CHAPPEY, O
    NIEL, E
    DERVICHIAN, M
    WAUTIER, JL
    SCHERRMANN, JM
    CATTAN, D
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (01) : 87 - 89
  • [30] Is compressed colchicine tablet superior to other colchicine preparations in patients with familial Mediterranean fever?
    Vasi, Ibrahim
    Kardas, Riza Can
    Yildirim, Derya
    Kaya, Burcugul
    Duran, Rahime
    Karadeniz, Hazan
    Guler, Aslihan Avanoglu
    Erden, Abdulsamet
    Kucuk, Hamit
    Goker, Berna
    Tufan, Abdurrahman
    Ozturk, Mehmet Akif
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (02) : 77 - 82